PMID- 26765068
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20220409
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Linking)
VI  - 64
IP  - 1
DP  - 2016 Jul
TI  - Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A 
      systematic review of efficacy and safety data.
PG  - 106-16
LID - 10.1002/hep.28453 [doi]
AB  - Transarterial chemoembolization (TACE) using lipiodol-based regimens, including 
      the administration of an anticancer-in-oil emulsion followed by embolic agents, 
      is widely used in the treatment of hepatocellular carcinoma (HCC). This approach 
      has been supported by meta-analyses of randomized, controlled trials (RCTs) 
      performed more than a decade ago. We performed a systematic review to understand 
      current efficacy and safety data of lipiodol TACE in treatment of HCC. A search 
      of the literature published between January 1, 1980 and June 30, 2013 was 
      performed using MEDLINE and EMBASE databases. All potentially relevant 
      publications were reviewed and articles were selected based on predefined 
      inclusion and exclusion criteria. Of a total of 1,564 articles reviewed, 101 
      articles, including a total of 10,108 patients treated with lipiodol TACE, were 
      selected for the efficacy analysis. Objective response rate was 52.5% (95% 
      confidence interval [CI]: 43.6-61.5). Overall survival (OS) was 70.3% at 1 year, 
      51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. Median OS was 19.4 
      months (95% CI: 16.2-22.6). A total of 217 articles presenting precise 
      description on numbers of adverse events (AEs) were selected for the safety 
      review: In these studies, a total of 21,461 AEs were reported in 15,351 patients. 
      Liver enzyme abnormalities were the most commonly observed AE, followed by the 
      symptoms associated with postembolization syndrome. Overall mortality rate was 
      0.6% and the most common cause of death was related to acute liver insufficiency. 
      CONCLUSIONS: In a systematic literature review, survival figures of HCC patients 
      undergoing lipiodol TACE appear to be in line with those reported in previous 
      RCTs, and no new or unexpected safety concerns were identified. (Hepatology 
      2016;64:106-116).
CI  - (c) 2016 by the American Association for the Study of Liver Diseases.
FAU - Lencioni, Riccardo
AU  - Lencioni R
AD  - Division of Vascular and Interventional Radiology, University of Miami Miller 
      School of Medicine, Miami, FL.
FAU - de Baere, Thierry
AU  - de Baere T
AD  - Department of Interventional Radiology, Institut Gustav-Roussy, Villejuif Cedex, 
      France.
FAU - Soulen, Michael C
AU  - Soulen MC
AD  - Division of Interventional Radiology, University of Pennsylvania, Radnor, PA.
FAU - Rilling, William S
AU  - Rilling WS
AD  - Division of Vascular and Interventional Radiology, Medical College of Wisconsin, 
      Milwaukee, WI.
FAU - Geschwind, Jean-Francois H
AU  - Geschwind JF
AD  - Department of Radiology and Biomedical Imaging, Yale University School of 
      Medicine, New Haven, CT.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160307
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - 0 (Antineoplastic Agents)
RN  - 8008-53-5 (Ethiodized Oil)
SB  - IM
CIN - Hepatology. 2016 Jul;64(1):23-5. PMID: 26991443
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Carcinoma, Hepatocellular/mortality/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - Ethiodized Oil/*administration & dosage/adverse effects
MH  - Humans
MH  - Liver Neoplasms/mortality/*therapy
EDAT- 2016/01/15 06:00
MHDA- 2017/07/25 06:00
CRDT- 2016/01/15 06:00
PHST- 2016/01/07 00:00 [received]
PHST- 2015/12/05 00:00 [revised]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
AID - 10.1002/hep.28453 [doi]
PST - ppublish
SO  - Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7.